
    
      The study includes dose-limiting toxicity （DLT）observing period and randomization period with
      two cohorts as low-dose group（Gentuximab Injection 8mg/kg+ paclitaxel） and high-dose
      group（Gentuximab Injection 12mg/kg+ paclitaxel）. During the study，the anti-cancer efficacy,
      safety and anti-drug antibody were evaluated in all patients. DLT observation is only to
      subjects enrolled in DLT observation period and it lasts one treatment period. PK were doing
      in part of subjects.
    
  